Negotiated procedure without prior publication of a tender notice, pursuant to art. 76, paragraph 2, letter b), of Legislative Decree no. 36/2023, for the supply of the exclusive drug Briumvi® required by APSS of Trento.

The Azienda Sanitaria Universitaria Integrata del Trentino (APSS di Trento) is undertaking a negotiated procedure, bypassing the need for a prior public tender notice as per art. 76, paragraph 2, letter b) of Legislative Decree no. 36/2023. The purpose is to secure the supply of the exclusive drug Briumvi®. This medication, Briumvi® (1 vial, Ev 6ml, 25mg/ml), is essential for APSS di Trento's operations. The estimated value for this supply contract is EUR 975,726.00, with the contract awarded to NEURAXPHARM ITALY S.P.A. for EUR 975,716.40. The procurement concerns various medicinal products.

This is a supplies contract in the general supplies sector, with a focus on General Supplies. Located in Italy, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 975,726.

Published through ANAC (Italy), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the general supplies sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.